Kornimate/medical-research-clean huggingface dataset:
plasticity of neonatal neuronal networks temporal theta activity, the first endogenous

Conditions: Premature Birth

Summary: temporal theta slow-wave activity (tta-sw) in premature infants is a specific signature of the early development of temporal networks, as it is observed at the turning point between non-sensory driven spontaneous local processing and cortical network functioning. the role in development and the precise location of tta-sw remain unknown. previous studies have demonstrated that preterms from 28 weeks of gestational age (wga) are able to discriminate phonemes and voice, supporting the idea of a prior genetic structural or activity-dependent fingerprint that would prepare the auditory network to compute auditory information at the onset of thalamocortical connectivity. they recorded tta-sw in 26-32 wga preterms. the rate of tta-sw in response to click stimuli was evalu- ated using low-density eeg in 30 preterms. the sources of tta-sw were localized by high-density eeg using different tissues conductivities, head models and mathematical models.

temporal theta slow-wave activity (tta-sw) in premature infants is a specific signature of the early development of temporal networks, as it is observed at the turning point between non-sensory driven spontaneous local processing and cortical network functioning. the role in development and the precise location of tta-sw remain unknown. previous studies have demonstrated that preterms from 28 weeks of gestational age (wga) are able to discriminate phonemes and voice, supporting the idea of a prior genetic structural or activity-dependent fingerprint that would prepare the auditory network to compute auditory information at the onset of thalamocortical connectivity. they recorded tta-sw in 26-32 wga preterms. the rate of tta-sw in response to click stimuli was evalu- ated using low-density eeg in 30 preterms.

Eligibility criteria:
inclusion criteria: * healthy premature infants * gestational ages of 26 and 32 wga exclusion criteria: * unhealthy premature infants

Keywords: temporoparietal areas neural biomarker
novel input screening tool to improve illness understanding in patients with metastatic or incurable lung cancer

Conditions: Lung Carcinoma; Metastatic Lung Carcinoma; Stage IV Lung Cancer AJCC v8

Summary: this clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the usual care to improve illness understanding in patients with lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or for which no curative treatment is currently available (incurable). goal concordant care is a model of care that aligns a patient's medical care with their values, preferences, and goals. often, patients may not fully understand their illness and prognosis, but this information is important so that they can make fully informed decisions regarding their care that are consistent with their values, preferences, and goals. completing the information needs, preferences, and understanding trial (input) screening tool may allow for more frequent and regular discussions regarding disease status and treatment goals, ultimately resulting in improved patient illness understanding and goal concordant care for patients with metastatic or incurable lung cancer.

primary objectives to estimate the within group effect of perception of curability over 3 months in both the systematic screening group and the usual care group among patients with metastatic or incurable lung cancer who present to the thoracic medical oncology clinic at the university of texas md anderson cancer center.

Eligibility criteria:
inclusion criteria: * within 3 months of biopsy-confirmed diagnosis of stage iv lung cancer * age 18 or over * english speaking * attending a follow-up visit at the thoracic medical oncology clinic * plans to receive or actively undergoing cancer-directed systemic treatment at md anderson exclusion criteria: • diagnosis of cognitive impairment or dementia requiring a surrogate decision maker
assesment of the efficacy of personalized parent-child psychotherapy in children under 3 years old

Conditions: Child Behavior Disorders; Parent-Child Relations

Summary: this study aims to assess the efficacy at 4 months of a personalized strategy comparatively to a standard psychodynamic integrative therapy, on childrens' symptom improvment

3 evaluations are performed: before treatment, at the end of the treatment and one year after the treatment. evaluations include assessment of: children's symptom parent-infant interaction quality parental competencies parental perception of the child by his/her parent parent-therapist alliance hair cortisol concentration

Eligibility criteria:
inclusion criteria: * families who are requesting a consultation for functional or behavioural problems of their child * children under the age of 3 exclusion criteria: * parents suffering from a severe untreated psychiatric disorder * difficulties in speaking french * children with autistic spectrum disorder * families already in care
complementary and integrative therapy for diabetic neuropathy

Conditions: Diabetes Mellitus, Type 2; Diabetic Neuropathy

Summary: despite the long tradition of complementary and alternative medicine (cam) therapies there are hardly any interventional trials on type 2 diabetes mellitus. hence this pilot study aims to investigate the influence of a two weeks integrative inpatient therapy on the quality of life in 50 patients suffering from diabetic neuropathy. integrative treatment includes aspects of conventional and traditional european and chinese medicine, mind-body medicine, physical therapy and lifestyle modification (nutrition advices, stress management and exercise training). the observational design intends four measurement points: tree months before (t0), directly before (t1), directly after treatment (t2) and three months follow-up (t3). the subjective evaluation of the neuropathy-related quality of life was combined with neurophysiologic instruments (qst), to measure neuropathic symptoms. also pain intensity, locus of control, interpretation of illness, coping style, anxiety/depression, life satisfaction and several biomarkers (hba1c, abi, whr and bmi) are measured. in addition a qualitative interview should give a view to patient perspective of therapy process.


Eligibility criteria:
inclusion criteria: * over 18 years old * diabetes mellitus type 2 exclusion criteria: * diabetes mellitus type 1 * pregnancy * oncologic diseases * systemic neurological diseases * other induced neuropathy (radicular, s/p alcohol abuse, chemotherapy-induced) * other severe psychiatric or somatic comorbidity

Keywords: diabetes mellitus, type 2 diabetic neuropathy complementary medicine alternative medicine integrative medicine quality of life quantitative sensory testing
prognostic and predictive factors for small breast tumors

Conditions: Breast Cancer

Summary: because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., t1abn0); these tumors account for approximately 19% of all newly diagnosed breast cancers in sweden. although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. firmly established prognostic and predictive factors for patients with t1abn0 tumors are, however, lacking. this is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. the study hypotheses are: 1) established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) the established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.


Eligibility criteria:
inclusion criteria: 1. female. 2. operated for centimeter or subcentimeter breast cancer. exclusion criteria: 1. previous breast cancer. 2. metastatic breast cancer at diagnosis.
consolidation & interference in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this research study is to investigate whether minimizing interference improves memory in multiple sclerosis.

the ability to form new long-lasting memories is important for successful independent living and a high quality of life. roughly half of the individuals diagnosed with multiple sclerosis (ms) have difficulty remembering new information and this is likely associated with poor acquisition of new information. there are only a limited number of studies that have investigated memory consolidation in ms. the current study will investigate the role of interference during the consolidation time period of memory formation.

Eligibility criteria:
inclusion criteria: * if you are between the ages of 18-65. * if you have a diagnosis of multiple sclerosis (ms) or are medically healthy. * if you have ms, you have not had a flare up of ms symptoms in the past month. * you do not have other neurological issues such as, epilepsy or stroke. * you do not have a significant history of psychiatric problems or a current diagnosis of major depressive disorder, schizophrenia, bipolar disorder . * you do not have a significant history of drug or alcohol abuse. * you can read and speak english fluently. * you are not currently taking steroids. exclusion criteria: * you are younger than 18 years old. * you are older than 65 years old. * you have had a prior stroke or neurological disease other than ms. * you have a history of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of major depressive disorder, bipolar disorder. * you have a significant alcohol or drug abuse history. * you are currently taking steroids.

Keywords: memory
a treatment-option protocol to provide brentuximab vedotin to eligible patients completing studies sgn35-005 or c25001

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous

Summary: the purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies sgn35-005 and c25001

the protocol was amended to reflect the change from a phase 2/3 to a study with an expanded access program (eap) in the us that would include patients with alcl and hl. a later amendment allowed patients with cd30-positive cutaneous t-cell lymphoma to enroll. enrollment may continue and patients may receive brentuximab vedotin treatment on study until the drug is commercially approved and available to patients in a geographic region.

Eligibility criteria:
inclusion criteria: * participated in either the sgn35-005 or c25001 clinical study and experienced progression. patients who received brentuximab vedotin in c25001 must have had an objective response at the time of discontinuation. * completed any previous treatment with radiation, chemotherapy, biologics and/or investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin exclusion criteria: * history of another primary malignancy that has not been in remission for at least 3 years * known cerebral/meningeal disease * peripheral neuropathy of grade 2 or greater * females who are pregnant or breastfeeding

Keywords: disease, hodgkin lymphoma monomethylauristatin e lymphoma, large-cell, anaplastic lymphoma, t-cell, cutaneous lymphoma, non-hodgkin antibodies, monoclonal antibody-drug conjugate antigens, cd30 hematologic diseases immunotherapy
perioperative smoking cessation interventions

Conditions: Smoking Cessation; Perioperative/Postoperative Complications

Summary: to assess impact of behavioral economic principles of precommitment, implementation intentions, and social contracting on smoking cessation for patients undergoing surgery.

purpose \& objective: behavioral interventions in surgical patients are an opportunity to improve outcomes through decreased complications, with measurable economic impact. smoking cessation is one of the most desirable long-term health behaviors for adults with potential substantial impact on postoperative complications study activity \& population group: the investigators propose a precommitment contractual agreement implementing behavioral economic principles at the preoperative appointment for active tobacco users undergoing an operation and assessing for ability to quit smoking with testing on the day of surgery, and the durability of cessation over the postoperative course as measured with urine nicotine testing at follow up appointments. the population of interest is adults who currently smoke tobacco or vaporized nicotine who are scheduled to undergo a major operation. the control group is standard of care; prescriptive advice to quit smoking. the intervention is contract agreement for preoperative cessation. data analysis \& risk issues: following informed consent patients will be randomized to control or intervention groups, baseline urine nicotine tests will be performed in clinic. urine nicotine testing will be performed on the day of enrollment, the day of their operation, and at their one-month follow up appointments. thirty-day outcomes will be evaluated by retrospective chart review.

Eligibility criteria:
inclusion criteria: * active tobacco use * preoperative appointment for an operation within 6 weeks exclusion criteria: * active enrollment in tobacco cessation program

Keywords: behavior perioperative/postoperative complications contract agreement implementation intentions precommitment smoking cessation
cold snare versus cold forceps polypectomy for small lesions

Conditions: Colorectal Adenoma; Colorectal Lesions

Summary: the goal of this clinical trial is to compare the efficacy and the safety of a new device for cold forceps polypectomy (cfp)- a special jumbo forceps- to cold snare polypectomy (csp) for small colorectal lesions, without adding peri- or post-procedural risks to the patient. the main questions it aims to answer are: * does the cold forceps guarantee a complete endoscopic resection rate? * how many adverse events could the jumbo forceps reduce in comparison to csp? * does the lesion retrieval rate increase? * does the polypectomy duration decrease? participants will be randomized to one or to the other group when a polypoid or non-polypoid lesion is identified. if multiple polyps are found in the same patient, they will be removed using the same polypectomy technique. if polypectomy cannot be performed using the indicated technique, a crossover will be done according to the best practice of care principles.

the study is a multicenter, prospective, randomized, controlled study. it is designed as a non-inferiority trial to assess whether the efficacy in polypectomy of the new jumbo cold forceps is non-inferior to that of the cold snare. the investigators hypothesize a less number of adverse events with cfp, an increased lesion retrieval rate and a less duration of the polypectomy procedure. all patients will be contacted, 30 days post-polypectomy, by blinded medical staff assessing for possible complications. all consecutive patients with polyp lesions can be enrolled, the participation is voluntary and randomization will be performed using the "minimization technique".

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years; * ability to provide informed consent; * presence of at least one colorectal polypoid/non-polypoid lesion \< 10 mm exclusion criteria: * primary or secondary coagulopathy; * improper interruption of dual antiplatelet therapy and/or antiplatelet therapy with p2y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor) and/or anticoagulant therapy; * chronic inflammatory bowel diseases; * inpatients undergoing colonoscopy; * colonoscopy as part of regional colorectal cancer screening; * pregnancy or breastfeeding

Keywords: cold forceps polypectomy colonoscopy cold snare polypectomy
phosphorus and calcium removal during long hemodialysis treatment sessions

Conditions: Kidney Failure

Summary: the purpose of this sudy is to determined the effect of dialysate volume and treatment time on phosphate and calcium removal in stage v chronickidney disease patients treated by hemodialysis using the system one (nxstage medical, lawrence, ma)

ten patients will be recruited from those routinely treated in-center or at home using the systerm one at the clinical centers. each patient will be studiesd on 4 separate occastions. treatments under the following conditions will each be performed on each study patient, at least one week apart: 1. treatment for 8 hrs uding 40l of dialysate 2. treatment for 8 hrs using 60l of dialysate 3. treatment for 5 hrs using 40l of dialysate 4. treatment for 5 hrs using 60l of dialysate blood samples will be collected and assayed for the concentrations of urea, phosphate, calcium, bicarbonate, beta-2-microglobulin and albumin using standard assays.

Eligibility criteria:
inclusion criteria: * stage v chronic kidney patients with minimal or no residual renal functin exclusion criteria: * medically unstable * hematocrit less than 28% * hepatitis b positive, hepatitis c positive or hiv positive * pregnant women * minors below 18 years of age * active psychiatric disease

Keywords: hemodialysis
effect of peep on subdural pressure, optic nerve sheath diameter, lung compliance and brain perfusion pressure

Conditions: Supratentorial Neoplasms; Anesthesia, General; Optic Nerve

Summary: we aim to determine the level of intraoperative peep that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize optic nerve sheath diameter measurement as an indicator for icp while optimizing lung compliance during supratentorial tumor surgeries.

application of positive end-expiratory pressure (peep) during general anesthesia minimizes ventilation/perfusion mismatch, intraoperative atelectasis and postoperative pulmonary complications. peep application in intracranial surgeries is usually avoided due to the risk of raised intracranial pressure (icp) leading to decreased cerebral perfusion pressure (cpp). several studies examine the effects of peep on subdural pressure and cpp however none examine how lung compliance is affected at the same time. ultrasound-guided measurement of optic nerve sheath diameter (onsd) is an indirect indicator of raised icp and there is limited literature on the correlation of onsd and icp during intracranial surgery. in this study, we aim to determine the level of intraoperative peep that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize onsd measurement as an indicator for icp while optimizing lung compliance during supratentorial tumor surgeries.

Eligibility criteria:
inclusion criteria: * supratentorial tumor * elective surgery * american society of anesthesiologist class i, ii or iii exclusion criteria: * midline shift more than 5 mm determined by intracranial imaging * initial subdural pressure higher than 20 mmhg * requiring intravenous mannitol or hypertonic saline treatment before dural opening * congestive heart failure * pulmonary hypertension * sepsis * hypovolemia * obstructive or restrictive lung disease
evaluation of lbl-003 phase i study in patients with advanced malignancies

Conditions: Advanced Malignant Tumor

Summary: this study is a single-arm, dose-escalation phase i clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of lbl-003 injection in patients with advanced malignant tumors.

the purpose of the single-dose escalation study of lbl-003 in subjects with advanced malignant tumors was to evaluate the safety and tolerability of monotherapy to determine the mtd (or mad) and to determine the clinically recommended dose of lbl-003 monotherapy. all subjects in this study underwent pharmacokinetic (pk) and pharmacodynamic (pd) studies. the dosing frequency of lbl-003 is once every 2 weeks (q2w), and the subsequent dosing frequency is adjusted according to the obtained pk and tolerability results. this study is expected to enroll 17-36 patients with solid tumors who have no standard treatment or have treatment failure with standard treatment or are not suitable for standard treatment at this stage.

Eligibility criteria:
inclusion criteria: 1. both male and female aged 18-75 years (including borderline values) at the time of signing the informed consent form; 2. ecog score: 0-1; 3. agree to follow the study treatment plan and visit plan, voluntarily enrolls, and signs the written informed consent. 4. subjects with advanced malignant solid tumors confirmed by histology or cytology have failed the standard treatment or have no standard treatment protocol or are not suitable for standard treatment at this stage. 5. subjects should have at least one evaluable lesion as defined by recist v1.1; 6. subjects are expected to survive at least 12 weeks; exclusion criteria: 1. history of immunodeficiency, including positive hiv antibody test results； 2. active hepatitis (hepatitis b or c)； 3. having undergone major surgery or still in the recovery phase of an earlier surgery within 4 weeks before the first administration; 4. women during pregnancy or lactation; 5. the investigator's assessment that there may be other factors affecting compliance among participants or that some may not be suitable for inclusion in this study.

Keywords: advanced malignant tumor
pulse waveform and ecg analysis in postoperative cardiac surgical patients

Conditions: Blood Pressure; Arrhythmias, Cardiac

Summary: observational study of 20 postoperative cardiac surgery patients. on admission to the icu the patients will receive a noninvasive monitor recording arterial pulse waveform and ecg. the monitoring will continue to the ward for two days. the data will be compared with the routine monitoring methods.

observational study of 20 adult postoperative cardiac surgery patients. the observation will last from 0 to 2. postoperative day. on admission to the icu the patients will receive a noninvasive monitor recording arterial pulse waveform and ecg. the monitoring will continue to the ward for two days. the data will be compared with the routine monitoring methods in the icu and the ward.

Eligibility criteria:
inclusion criteria: * adult cardiac surgery patients, informed consent exclusion criteria: * poor co-operation, age less than 18 years